Biotech · Private company
Cerenome
Track this companyFree. Adds Cerenome to your Dealase workspace and tells you when its record changes.
Clinical trials54 recruiting or active
Pipeline programs4From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline4
- 186RNLPhase 2 · Leptomeningeal MetastasisClinicalTrials.gov · fetched Nov 12, 2026
- Rhenium Liposome TreatmentPhase 2 · GliomaClinicalTrials.gov · fetched Nov 12, 2026
- Retreatment Rhenium LiposomePhase 1 · GliomaClinicalTrials.gov · fetched Nov 12, 2026
- Rhenium-186 NanoliposomePhase 1 · EpendymomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials5
- Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade GliomaPHASE1 · RECRUITING · started Aug 1, 2026ClinicalTrials.gov NCT07061626 · fetched Nov 12, 2026
- Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal MetastasesPHASE1_PHASE2 · RECRUITING · started Jul 2, 2025ClinicalTrials.gov NCT07098806 · fetched Nov 12, 2026
- Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL TreatmentPHASE1 · RECRUITING · started Dec 12, 2024ClinicalTrials.gov NCT05460507 · fetched Nov 12, 2026
- Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal MetastasesPHASE1 · COMPLETED · started Dec 6, 2021ClinicalTrials.gov NCT05034497 · fetched Nov 12, 2026
- Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)PHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Jun 3, 2015ClinicalTrials.gov NCT01906385 · fetched Nov 12, 2026